All In Biotech

Investigational drug · Phase 2

Vortosiran

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis).

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "Vortosiran"

First trial start

2026

Oct 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Vortosiran", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Venous Thromboembolism (VTE)
  • Cancer
  • Pulmonary Embolism (Diagnosis)
  • Non-valvular Atrial Fibrillation (AF)

Approved drugs for the same conditions: Atrial fibrillation · Blood clots (DVT and pulmonary embolism) · Oncology · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Vortosiran" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Venous Thromboembolism (VTE)

  • REGN7508CenvacibartPhase 312 trials

    Regeneron · Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism

  • REGN9933amrecibartPhase 35 trials

    Regeneron · Atrial Fibrillation (AF), Peripheral Artery Disease (PAD), Venous Thromboembolism (VTE)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.